OncBioMune Pharmaceuticals, Inc. announced that Concurrently with the closing of the Asset Purchase Agreement, the Board of Directors appointed the Chief Executive Officer of Avant, Mick Ruxin, M.D., to serve as new Chief Executive Officer. Andrew Kucharchuk, who has resigned from his position as Chief Executive Officer.